



GREENBROOK TMS CENTERS BEGIN TO TREAT OBSESSIVE COMPULSIVE DISORDER WITH TMS THERAPY

November 8, 2018 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“**Greenbrook**” or the “**Company**”), a leading provider of Transcranial Magnetic Stimulation (“**TMS**”) therapy in the United States for the treatment of Major Depressive Disorder (“**MDD**”), is pleased to announce that its TMS Centers will begin to offer treatment for Obsessive Compulsive Disorder (“**OCD**”). The treatment, which will be rolled out throughout the Company’s TMS Center network, delivers targeted magnetic pulses into the region of the brain implicated in OCD. As with all other TMS therapy provided at Greenbrook’s TMS Centers, this outpatient, office-based treatment is FDA-cleared, safe and non-invasive. Patients can resume daily activities immediately following a treatment session.

OCD is a condition which causes intrusive and recurring obsessions and/or compulsions that interfere with a person’s daily activities and quality of life. Over 2 million adults in the United States are diagnosed with OCD each year. Conventional OCD treatments are only effective in about 50% of cases.

Dr. Geoffrey Grammer, Chief Medical Officer of the Company stated: “The launch of this OCD treatment demonstrates our commitment to utilizing the latest developments in Transcranial Magnetic Stimulation to offer our patients the very best care possible. The H7 coil system developed by Brainsway provides us the new capability to treat areas of the brain involved in OCD and provide patients a truly novel approach to symptom relief.”

About Greenbrook TMS Inc.

Operating through 48 Company-operated treatment centers, Greenbrook is a leading provider of TMS, an FDA-cleared, non-invasive therapy for the treatment of MDD and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 160,000 TMS treatments to over 4,500 patients struggling with depression.

Forward-Looking Information

Certain information in this press release constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this press release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the “Risk Factors” section of the Prospectus available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The

forward-looking statements contained in this press release are made as of the date of this press release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

For further information please contact:

Erns Loubser
Chief Financial Officer, Treasurer and Corporate Secretary
Greenbrook TMS Inc.
investorrelations@greenbrooktms.com
1-855-797-4867